. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: Ann Surg Oncol. 2020 Nov 24;28(7):3779–3788. doi: 10.1245/s10434-020-09391-9

TABLE 3.

IPWE-based ATE depicting the impact of NCRT on survival of patients with PDAC

Median survival (95%CI)		p value (log-rank sum test)	ATE (NCRT) (95%CI)	p value (ATE)
NCRT (N =91)	NAC (N = 327)	p value (log-rank sum test)	ATE (NCRT) (95%CI)	p value (ATE)
DFS
17.02 (15.15, 19.52)	16.16 (14.82, 18.14)	0.652	9.5 (2.8, 16.2) ^*	0.006
OS
31.44 (23.85, 42.02)	31.21 (28.42, 38.64)	0.330	5.4 (−5.2, 16.1)^**	0.318

Bold value denotes staistical significance p < 0.05

NAC neoadjuvant chemotherapy, NCRT neoadjuvant chemoradiotherapy, ATE average treatment effect, 95%o CI 95% confidence interval, DFS disease-free survival, OS overall survival

DFS analysis after matching for: gender, resectability, baseline CA19-9, NAC regimen, NAC cycles, receipt of adjuvant chemotherapy, and adjuvant RT.

^**

OS analysis after matching for: age, gender, BMI, diabetes, resectability at diagnosis, NAC regimen, number of NAC cycles, preoperative albumin, mode of surgery, receipt of adjuvant chemotherapy and radiotherapy, and recurrence